Also known as Ocrevus.
Phase III data showed ARR reductions of 51% and 58% vs teriflunomide and a numerical 12% reduction in PPMS progression versus ocrelizumab; CNS‑penetrant, non‑covalent BTK inhibitor.
CHMP backs ocrelizumab for relapsing MS in patients aged 10 and older after Phase III showed stronger lesion suppression and comparable relapse control versus fingolimod.
